Simvastatin is an HMG-CoA reductase inhibitor that lowers the production of cholesterol in the liver. Its primary healthspan relevance is the profound reduction of atherosclerotic cardiovascular disease (ASCVD) risk, a leading driver of mortality and morbidity in aging populations.
Verdict
A foundational tool for managing cardiovascular risk, a key longevity pillar.
HEALTHSPAN IMPACT
Foundational
RISK LEVEL
Moderate
EVIDENCE GRADE
A
MONTHLY COST
$5 - $25
Protocol
- Daily dosages of 10-40 mg are common for managing hyperlipidemia under medical supervision.
Flags
- Risk of muscle pain (myalgia) and, rarely, severe muscle damage (rhabdomyolysis).
- Associated with a small but statistically significant increased risk of developing type 2 diabetes.
- Interacts with grapefruit juice and certain medications like fibrates and some antifungals.
- Requires a prescription and medical supervision for use.